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Abstract
Background: Osteoradionecrosis of the mandible is the most common serious complication of radiotherapy for
head and neck malignancy. For decades, hyperbaric oxygen has been employed in efforts to prevent those cases of
osteoradionecrosis that are precipitated by dental extractions or implant placement. The evidence for using hyperbaric
oxygen remains poor and current clinical practice varies greatly. We describe a protocol for a clinical trial to assess the
benefit of hyperbaric oxygen in the prevention of osteoradionecrosis during surgery on the irradiated mandible.
Methods/design: The HOPON trial is a phase III, randomised controlled, multi-centre trial. It employs an unblinded trial
design, but the assessment of the primary endpoint, i.e. the diagnosis of osteoradionecrosis, is assessed on anonymised
clinical photographs and radiographs by a blinded expert panel. Eligibility is through the need for a high-risk dental
procedure in the mandible where at least 50-Gy radiotherapy has been received. Patients are randomised 1:1 to
hyperbaric oxygen arm (Marx protocol) : control arm, but both groups receive antibiotics and chlorhexidine mouthwash.
The primary endpoint is the presence of osteoradionecrosis at 6 months following surgery, but secondary endpoints
include other time points, acute symptoms and pain, quality of life, and where implants are placed, their successful
retention.
Discussion: The protocol presented has evolved through feasibility stages and through analysis of interim data. The
classification of osteoradionecrosis has undergone technical refinement to ensure that robust definitions are employed.
The HOPON trial is the only multi-centre RCT conducted in this clinical setting despite decades of use of hyperbaric
oxygen for the prevention of osteoradionecrosis.
Trial registration: European Clinical Trials Database, ID: EudraCT200700622527. First registered on 5 November 2007.
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Background
Osteoradionecrosis (ORN) describes the process where
irradiated bone undergoes necrosis and becomes ex-
posed through the investing soft tissues for a period of
at least 3 months [1–3]. An important precipitating fac-
tor for mandibular ORN is surgical trauma, commonly
dental extractions or implant placement following head
and neck radiotherapy, but ORN can also occur spon-
taneously. ORN is painful and debilitating, often requir-
ing surgical resection of the jaw and complex
multidisciplinary management [4]. The morbidity and
mortality of ORN is significant and treatment outcomes
often unsatisfactory. Post-radiation extractions should,
self-evidently, be performed atraumatically and antibi-
otics are commonly prescribed [5], but there is a paucity
of high-quality evidence to guide best practice in the
prevention of ORN.
Preventive approaches include pre-radiotherapy ex-
traction of teeth and the use of hyperbaric oxygen
(HBO) treatments or prophylactic antibiotics for post-
radiotherapy extractions [6]. The overall incidence of
ORN among post-radiotherapy patients is not certain
but may have declined with improvement of radiother-
apy techniques including intensity-modulated radiother-
apy (IMRT) over recent decades [7]. However, the
incidence of head and neck cancer, the proportion of
cases receiving radiotherapy, and prognosis are all in-
creasing [8], contributing to an expansion in the ‘at risk’
population where ORN prevention must be addressed.
The risk of ORN with dental extractions is higher in the
posterior mandible, with radiotherapy doses higher than
60 Gy (or with brachytherapy) and in smokers [9].
There have only been limited trials of prophylactic
HBO. The single-centre randomised controlled trial
(RCT) by Marx et al. [10] showed a significantly lower
incidence of ORN after post-radiotherapy dental extrac-
tions in the HBO group when compared with the con-
trol group. There were two cases of ORN in 37 patients
(5.4%) receiving HBO undergoing 156 extractions, com-
pared with 11 cases in 37 patients (29.9%) undergoing
135 extractions receiving prophylactic penicillin, result-
ing in a number needed to treat (NNT) of 4. In a non-
randomised retrospective study, Vudiniabola et al. [11]
showed that of 29 patients who received pre-extraction
HBO, 1 (3.4%) developed ORN; and of 7 patients who
did not receive HBO, 1 (14.3%) developed ORN. Despite
improvements in radiotherapy since the time of these
studies, and evidence of a decreasing incidence of ORN
[12], prophylactic HBO to prevent ORN has remained a
standard of care for high-risk dental extractions [13].
HBO is not available to all patients as it requires prox-
imity to a chamber, it is costly (approximately
£4000–6000 per course) and sometime logistically prob-
lematic, requiring multiple daily visits. A typical protocol
for prevention dictates 45 h of treatment over 30 com-
pressions [10]. There are also risks associated with HBO
therapy. A comprehensive recent safety review [14]
noted common temporary visual problems, Eustachian
tube problems 2%, claustrophobia 2% and seizure < 0.01.
A survey of UK practice revealed that, in a high-risk
extraction of a lower mandibular molar, 33% ‘never’, 41%
‘sometimes’ and 26% ‘usually’ or ‘always’ prescribe
prophylactic HBO [15]. Questionnaires of attitude to
RCTs for HBO revealed that 93% of responders would
wish to recruit such patients into multi-centre RCT [16].
Additionally, there is a lack of agreement on HBO
protocol, with some UK patients referred for treatment
in centres using non-standard pressures [17], lower than
the typical 2.4 atmospheres (ATA) recommended in
most ORN publications. Current National Institute for
Health and Care Excellence (NICE) guidelines on the
management of ORN recommend the use of HBO only
as part of a clinical trial [18].
An additional question regarding the efficacy of HBO
surrounds the placement of osseointegrated implants
into the irradiated mandible, with the aim of preventing
ORN or optimising bony healing and implant retention.
Survey data again suggest wide disparity in practice [15]
in the UK. No RCT has been carried out in this setting,
and there are conflicting data from retrospective case
control series [19, 20] as to whether HBO may enhance
survival of implants in irradiated bone.
Objective
The objective of the HOPON trial is to determine the
benefit of HBO in the prevention of ORN subsequent to
a surgical procedure in the ‘at risk’ irradiated mandible.
The procedures included are high-risk dental extractions
and the placement of implants. Additional outcomes are
to document the incidence of ORN in the control group,
the outcomes where ORN is diagnosed, and the reten-
tion of implants. The trial will also measure the effect of
HBO in post-operative pain and effects on quality of life.
The HOPON phase III trial protocol described here has
evolved from the feasibility objectives in a preceding
HOPON feasibility study.
Methods/Design
Design
HOPON is a prospective, multi-centre, randomised con-
trolled, phase III trial to assess the effectiveness of
preventing ORN after surgical procedures in the irradi-
ated mandible. Although the patients and investigators
are unblinded, the primary endpoint is assessed by a
blinded panel for the presence and grade of ORN. Other
endpoints are unblinded as they are recorded by either
the patients or site investigators.
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Study population and eligibility
Patients who meet the eligibility criteria (Table 1) will be
recruited either from routine review following the treat-
ment of head and neck cancer, or following referral for
oral rehabilitation. Detailed information on the benefits
and risks of the study will be provided to the patients,
including the provision of HBO at the nearest suitable
trial chamber.
Randomisation and blinding
Patients who meet eligibility criteria and have given in-
formed consent will be randomly assigned by the Cancer
Research UK Liverpool Cancer Trials Unit (LCTU).
Randomisation will be in a 1:1 ration between HBO arm
and control (non-HBO) arm, stratified by recruiting
centre. The randomisation code list will be generated by
the LCTU trial statistician by means of block random-
isation [21] with randomly varying block length. The
clinical team will be informed of the allocation of each
patient by fax. Allocation of treatment is unblinded to
local investigators and patients. The trial schema is
shown in Fig. 1.
Trial intervention and control treatments
The supplier of the oxygen to be used will be dependent
on standard practice within each hyperbaric unit. Treat-
ment will be administered based around a version of the
Royal Navy Therapeutic Table 66 – Repeat Hyperbaric
Oxygen Therapy [22]. The patient undergoes pressurisa-
tion to 2.4 ATA at a tolerable rate. The patient under-
goes decompression after 100% oxygen has been
breathed at 2.4 ATA for a total of between 80 and
90 min. Air breaks while at 2.4 ATA may be introduced
routinely or as required. The decompression is sched-
uled to control satisfactorily any risk to the patient and,
if present, to the in-chamber attendant. Patients should
breathe oxygen at an inspired partial pressure greater
than 2.0 ATA for no more than 110 min during each in-
dividual treatment.
Patients in both arms of the trial are given chlorhexi-
dine mouthwash and antibiotics. Pre- and post-operative
chlorhexidine mouthwash 0.2% is used in a volume of
10 ml (i.e. one capful) washed around the mouth for
around 1 min and spat out, three times daily (tds) for
5 days post-operatively. In case of chlorhexidine allergy,
warm salt mouthwash at 1 teaspoon per cup of warm
water is used. Orally administered antibiotics comprise
amoxicillin 3 g 1 h pre-operatively (or 1 g administered
intravenously) and 250 mg tds for 5 days post-
operatively. In case of penicillin allergy this will be:
600 mg orally administered clindamycin (either 600-mg
tablets orally (or the same dose of a 75-mg/5 ml suspen-
sion if tablets not tolerated) given 1 h pre-operatively (or
600 mg administered intravenously at the time of sur-
gery) and 200 mg metronidazole orally tds for 5 days
post-operatively.
Outcome measures
The primary outcome measure is the diagnosis of ORN
6 months following surgery as determined by a blinded
central review of clinical photographs and radiographs
as well as the site investigator’s assessment. This blinded
review is carried out by an expert panel, with access to
paired clinical photographs and radiographs (orthopan-
tomogram). Additionally, where possible, any area of
exposed bone is presented in context of an in-field rule
and/or site investigator’s measurement on the case
report forms. The diagnosis of ORN at 3 and 12 months
are secondary outcome measures, but determined in a
similar way, the only difference being that radiographs
will only be taken at these time points if ORN has been
clinically diagnosed. A summary of the outcome mea-
sures and their time points is presented in Table 2.
The definition and classification of ORN used in the
trial, based on that of Notani [23], has been subject to a
technical refinement through protocol amendment fol-
lowing blinded analysis of the HOPON feasibility data
[24], and is presented in Fig. 2. This was required to re-
solve inconsistencies which arose in cases where very
small areas of exposed bone were seen: ‘minor bone
spicules’ (MBS) were apparent, which occurred in 19%
of patients in this initial analysis. In reporting cases with
MBS, some trial investigators took a pragmatic position
in judging MBS as clinically unimportant, likely grad-
ually healing, and not reflecting progressive ORN.
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Age > 18 years
Prior radiotherapy to mandible > 50 Gy
No evidence of cancer recurrence
Condition requiring surgery to mandible:
Extraction of premolar or molar
Implant placement
Provision of written informed consent in competent patient
Prior diagnosis of ORN of the mandible
Prior HBO therapy for any indication
Any previous prescription of systemic bisphosphonates, pentoxyphylline or tocopherol
Pregnancy
Contraindications to HBO:
Lung disease (severe COPD or bullae)
Middle ear
Claustrophobia
COPD chronic obstructive pulmonary disease, HBO hyperbaric oxygen, ORN osteoradionecrosis
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Others classified as Notani 1 ORN based on rigid
definitions in common clinical use. When MBS was
added as an additional distinct category to the classifica-
tion (as < 20 mm2) this ambiguity was resolved and
agreement between observers was achieved. This refine-
ment was adopted by the protocol after discussion with
trial oversight committees and the relevant regulatory
bodies. A working assumption was made, after consult-
ation, to group MBS with the healed (‘not ORN’) cases,
but another outcome measure of the trial will be to test
this assumption against the outcomes for later time
points. For the purpose of the HOPON trial, radiological
signs alone, or pain alone, are not considered ORN unless
accompanied by a breach in overlying skin or mucosa.
As the primary endpoint of the trial is dependent on the
availability and quality of radiographs and clinical photo-
graphs, a quality-control protocol is adopted. All new cen-
tres recruiting patients will have the first sets of images
audited, and then 10% thereafter. These will be scored as
adequate/inadequate to assess the presence of ORN by an
appropriate panel assembled, viewed independently by
three qualified clinicians, on reviewing anonymised im-
ages. Any centres submitting photographs of inadequate
standard will be offered advice and training.
The schedule of enrolments, interventions and assess-
ments is summarised using the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
schedule as Fig. 3; and the SPIRIT Checklist provided as
Additional file 1.
Safety and adverse event reporting
Standard definitions and procedures for the manage-
ment of adverse events (AE), serious adverse events
(SAE), serious adverse reactions (SAR) and suspected
unexpected serious adverse reactions (SUSAR) are
adopted within the trial. AEs and reactions are reported
using relevant Case Record Form (CRF), whether re-
lated to treatment or disease, within 28 days following
the last trial treatment. This will be antibiotics and
mouthwash in the control arm, and HBO in the treat-
ment arm. In addition, a new diagnosis of cancer or
Fig. 1 Hyperbaric Oxygen for the Prevention of Osteoradionecrosis (HOPON) trial schema (Consolidated Standards of Reporting Trials (CONSORT) format)
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recurrence of cancer will be reported as an SAE for the
duration of the patient’s involvement in the study up to
12 months after surgery, irrespective of whether this is
related to head and neck cancer, or the original indica-
tion for radiotherapy.
Statistical considerations
Sample size
Assuming an ORN rate of 5% in the HBO arm at
6 months following surgery consistent with an earlier
RCT [10], 103 evaluable patients per group would
Fig. 2 Criteria for diagnosis of osteoradionecrosis (ORN) in the Hyperbaric Oxygen for the Prevention of Osteoradionecrosis (HOPON) trial [24].
ORN, further classified [23]: Notani 1: ORN confined to alveolar bone. Notani 2: limited to the alveolar bone and/or above the level of the inferior
alveolar canal. Notani 3: ORN under the lower part of the inferior alveolar canal, with fistula or bone fracture
Table 2 Outcome measures, time of assessment and method of assessment
Outcome measure Timing Method of assessment
Primary outcome
Presence of ORN 6 months Blinded review of radiograph, clinical photograph with corroboration from site investigator’s
assessment in CRF (and dimensions of any exposed bone)
Secondary outcomes
Presence of ORN 3 and 12 months As primary endpoint, but without radiographs unless ORN clinically evident
Severity of ORN 3, 6 and 12 months Blinded review of radiograph, clinical photograph, site investigator’s assessment (and
dimensions of any exposed bone) using modified Notani Score [23, 24]
Quality of life 3, 6 and 12 months University of Washington head and neck cancer questionnaire
Pain following surgery 3, 6 and 12 months Patient-reported on a Visual Analogue Scale and use of analgesia
Acute symptoms Days 1 thru 7 post
surgery
Patient-reported Likert scale for pain, swelling, trismus, normalcy of diet
Assessment of implants
(where relevant)
At closure of trial Casenote review, by loss of any implant placed as part of trial
Late follow-up of MBS cases
(where relevant)
At closure of trial Casenote review, by severity of ORN using modified Notani Score [23, 24].
Safety of HBO related to
cancer recurrence
Within 12 months of
trial treatments
SAE reporting.
Safety of HBO, otherwise Within 28 days of HBO AE/ SAE reporting of symptoms related to hyperbaric treatment
AE adverse event, CRF Case Record Form, HBO hyperbaric oxygen, MBS minor bone spicules, ORN osteoradionecrosis, SAE serious adverse event
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provide 80% power to detect an odds ratio of 0.23
(equivalent to detecting an absolute difference of 13.5%
between treatment arms) at a 5% two-sided significance
level. An estimated dropout rate was extrapolated from
feasibility data at 7%, resulting in an estimate of 221 pa-
tients to be recruited in total.
Analysis plan
It is not planned to fully adhere to the intention-to-treat
(ITT) principle of ‘analysing as randomised’ because pa-
tients do not have the intervention (HBO or standard
care) until they have been randomised and had surgery ar-
ranged. Feasibility data revealed a somewhat higher drop-
out rate after randomisation in the HBO arm because of
the increased opportunity available in the time taken to
schedule HBO. Furthermore, the clinical question to be
answered is the effect of HBO, but only among those
receiving surgery, and not the effect of HBO in itself.
Demographic and clinical factors for the HBO and control
groups will be presented both ‘as randomised’ and also ‘as
receiving surgery’. A multiple logistic regression analysis
will be performed to confirm that these factors remain
jointly uninformative for receiving surgery.
The primary test of efficacy in terms of risk of ORN at
6 months will be carried out using an exact logistic regres-
sion including a fixed term for treatment arm. The null
hypothesis is that inclusion of HBO treatment pre-surgery
is not more effective than standard care alone; that is, the
odds ratio is not statistically different from 1, while the
alternate hypothesis is that HBO treatment is superior to
standard care with an odds ratio of 0.23 or less. The test
will be two-sided and a P value of less than 0.05 will be
declared statistically significant. Two-sided 95% confi-
dence limits for the odds ratio will be presented for
consistency with the significance test. Significance tests
for secondary endpoints will also be two-sided at 5%
accompanied by 95% two-sided confidence intervals.
Interim analyses
A feasibility stage was incorporated into the original
funding application with endpoints of ability to recruit,
randomise and complete trial protocols for 50 patients
within 2 years of commencement. Following this, regular
analyses of trial data by the Independent Safety Data
Monitoring Committee (ISDMC) review occur at
12-monthly intervals to assess recruitment rates and
toxicity. A single, formal interim analysis will be carried
out when 100 dental extraction patients have been
followed up to the primary endpoint at 6 months. The
Peto stopping rule will be implemented for the primary
efficacy outcome (ORN rate at 6 months following
surgery), and a futility analysis will also be carried out.
Sensitivity analyses
These will consist of:
1. Assessing the effects of assuming that:
Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) trial schedule
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(a)all pre-surgery dropouts would have developed
ORN
(b)no pre-surgery dropouts would have developed
ORN
(c)all pre-surgery dropouts would have developed
ORN with risk for their arm
(d)all pre-surgery dropouts would have developed
ORN with mean risk across both arms
2. Assessing the effect of adjustment in analysis of the
primary outcome for radiotherapy dose, age, sex,
tobacco and alcohol use
3. Inclusion of multiply imputed primary endpoint
responses for all randomised patients
4. Comparison of results using the site principal
investigator’s (PI’s) original assessment of ORN
(as with the primary analysis, this will include
assessment of centre effects)
5. Analysis of ‘blinded review’ ORN after including
MBS vs excluding cases with only MBS
Translational research
In addition to the routine trial assessments, translational
blood samples will be taken either at the time of surgery,
or at any time after randomisation. Sample collection
kits will be sent to all participating sites and the samples
collected and stored to Good Clinical Laboratory
Practice (GCLP) standard at the University of Liverpool.
These samples will be used at a future date to discover/
evaluate potential biomarkers of the genomic determi-
nants of ORN [25].
Trial oversight and regulatory arrangements
Trial Management Group (TMG)
This comprises the chief investigator (CI), other lead in-
vestigators (clinical and non-clinical) and members of
the LCTU. The TMG will be responsible for the day-to-
day running and management of the trial and will meet
approximately monthly.
Trial Steering Committee (TSC)
The TSC will consist of the TMG plus three independ-
ent members, two patient representatives and an inde-
pendent chair. The TSC will provide overall supervision
for the trial and provide advice through its independent
chair. The ultimate decision for the continuation of the
trial lies with the TSC.
Independent Safety Data Monitoring Committee (ISDMC)
The ISDCM will be responsible for reviewing and asses-
sing recruitment, interim monitoring of safety and ef-
fectiveness, trial conduct and external data. The ISDMC
will first convene prior to trial opening and will then
define frequency of subsequent meetings (at least
annually). The ISDMC will provide a recommendation
to the TSC concerning the continuation of the study.
Sponsorship
The HOPON trial is co-sponsored by the University of
Liverpool and Aintree University Hospitals NHS
Foundation Trust.
Registration
The HOPON trial is registered with the European
Clinical Trials Database (EudraCT 2007-006225-27).
Clinical trial authorisation
The HOPON trial uses oxygen which is classified by the
Medicines and Healthcare Products Regulatory Authority
(MHRA) as an Investigational Medicinal Product. The
trial has received a clinical trial authorisation by the
MHRA under the Medicines For Human Use (Clinical
Trials) Regulations 2004 S.I. 2004/1031 (MHRA reference:
04196/0010/001-0019).
Discussion
Several areas of controversy have arisen during the de-
velopment of the HOPON protocol. The first of these is
the need for blinding. Some comparable trials in other
fields of late radiation toxicity have used a sham HBO
arm with the aim of producing a double-blind trial [26–
28]. The sham HBO arm used in such trials varies con-
siderably. One approach [26] utilises a breathing mixture
of 9% oxygen and 91% nitrogen so that at 2.4 ATA, ar-
terial PaO2 is similar to breathing 21% oxygen at ambi-
ent air pressure. This, however, still exposes patients to
the documented risks of hyperbaric pressure, and is by
some considered unethical because of the implied issues
of safety without any chance of benefit. Another ap-
proach used 40% oxygen and 60% nitrogen [28] provid-
ing an alternative lower ‘dose’ of oxygen treatment and
correlation of outcome rather than a true control arm.
More recently [27, 29] sham HBO arm using air at 1.1
ATA [29] or 1.3 ATA [27] have been used to provide a
minimal increase in partial pressure of oxygen (PpO2)
while providing the sensations of compression. Regard-
less of mode of delivery, the provision of sham HBO
treatments are equivalent in cost to those delivered on
the treatment arm which, given finite resources, may im-
pact the cost-effectiveness of such research. Finally, it is
also uncertain whether the HBO chamber staff could
ever be effectively blinded as they remain in control of
the chamber. It is, therefore, possible that patients be-
come unblinded when treated for over 30 treatment ses-
sions, particularly as these sham treatments are
delivered at a regular and different daily session to the
oxygen treatments.
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The need for a blinded trial using sham treatments is
considered desirable in trials where the primary end-
point is subjective or employ patient-reported outcome
measures. In the HOPON trial the primary outcome is
the presence of ORN, which is considered more object-
ive, and additionally can be assessed on clinical photo-
graphs and radiographs at a remote time and location,
by a panel of investigators who are blinded to the treat-
ment arm received. However, the unblinded trial design
for HOPON does introduce the possibility of reporting
bias in some of the more subjective secondary outcomes
such as quality of life or pain. Further, the unblinded de-
sign of the trial and need for extra treatments in the
HBO arm introduces an inequality in time between ran-
domisation and surgery for that arm. This potential
methodological concern means that the time points
commence at the time of surgery, rather than the date of
randomisation, where it might be argued that only at
randomisation are the two groups truly comparable.
Another difficulty that has arisen during the feasibility
stage of the trial is the difficulty in robust allocation of
some early stages of ORN. These have subsequently
been classified as minor bone spicules (MBS), but are
not reflected within any of the classifications of ORN
currently in use. This difficulty is presumably not unique
to the HOPON trial, yet it is difficult to ascertain from
other similar studies how such cases have been dealt
with. This is a problem created by taking a working
‘textbook definition’ of a clinical condition and extrapo-
lating it as a primary outcome measure in a clinical trial.
Because of the frequent (19%) finding of MBS during a
blinded interim data review, it was logical to introduce
an additional class to reflect this, the justification for
which has been separately published [24]. To establish if
any of the MBS cases in the HOPON trial will progress
to clinically significant ORN, there is a secondary out-
come measure of outcome of such patients at the
conclusion of the trial. As a means to avoid any ambigu-
ity, therefore, the use of the Notani classification with
the additional category of MBS has been employed in
order to avoid subjectivity and to enhance reliability and
consistency of reporting.
Further concerns were around how to deal with miss-
ing data, dropouts and the effect of differing complexity
and length of treatment between the two arms. While
ITT analysis is usual practice for the primary analysis in
superiority trials, in this trial ‘analysing as randomised’
would not answer the clinical question which relates to
a fixed time following surgery, in other words the
intended primary analysis is essentially on a per-protocol
or treatment-received basis. While unusual, this is one
of the circumstances in which, as Piantadosi [30] has
pointed out, too strict adherence to the ITT principle is
unhelpful or inappropriate.
The HOPON trial design has, therefore, evolved
through analysis of feasibility data and through blinded
interim data analysis. This is the only formally con-
ducted, multi-centre, RCT conducted in this field that
the authors are aware of, and it is the first since Marx’s
single-centre study [10] published over three decades
ago. The trial will provide data on the incidence of ORN
after dental extraction and implant placement as well as
the effect of HBO on retention of implants. Importantly,
HOPON will provide translational resource for future
studies of the genomic determinants of ORN in a group
of patients treated to a defined protocol.
Trial status
Feasibility and interim analysis complete. Patient recruit-
ment and data collection is ongoing to Protocol 9, dated
11 January 2017.
Additional file
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